Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia

BACKGROUND: Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation. A critical question is whether this phenomenon may also occur when ibrutinib is temporarily held. This study aimed to determine the frequency and chara...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hampel, Paul J., Call, Timothy G., Rabe, Kari G., Ding, Wei, Muchtar, Eli, Kenderian, Saad S., Wang, Yucai, Leis, Jose F., Witzig, Thomas E., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Van Dyke, Daniel L., Braggio, Esteban, Slager, Susan L., Kay, Neil E., Parikh, Sameer A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Hematologic Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648348/
https://ncbi.nlm.nih.gov/pubmed/32886416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0388
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados